Alpha-Thujaplicin

Alpha-Thujaplicin

SCHEMBL355645

CC(C)c1ccccc(O)c1=O

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 4/20 0.67
GABRB2 P47870 2/20 0.67
CA2 P00918 3/20 0.50
CYP3A4 P08684 3/20 0.50
HPGD P15428 3/20 0.50
HIF1A Q16665 3/20 0.50
LMNA P02545 3/20 0.50
TSHR P16473 2/20 0.50
CA1 P00915 2/20 0.50
FAAH O00519 2/20 0.50
CYP1A2 P05177 2/20 0.50
GABRB1 P18505 2/20 0.50
GABRG2 P18507 2/20 0.50
GABRB3 P28472 2/20 0.50
BLM P54132 2/20 0.50
PTGS1 P23219 1/20 0.50
SLC6A2 P23975 1/20 0.50
HTR2C P28335 1/20 0.50
GABRA5 P31644 1/20 0.50
GABRA3 P34903 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL524689 0.83 HPGD (0.64) GABRA1GABRB2CA2CYP3A4HPGD
Hydrochloric Acid SCHEMBL6040027 0.81 GABRA1 (0.90) GABRA1GABRB2CA2CYP3A4HPGD
SCHEMBL29531559 0.80 GABRA1 (1.00) GABRA1GABRB2CA2CYP3A4HPGD
SCHEMBL43297 0.80 GABRA1 (1.00) GABRA1GABRB2CA2CYP3A4HPGD
SCHEMBL15485453 0.80 GABRA1 (1.00) GABRA1GABRB2CA2CYP3A4HPGD
Formaldehyde SCHEMBL27606839 0.79 GABRA1 (0.86) GABRA1GABRB2CA2CYP3A4HPGD
Benzene SCHEMBL1841233 0.78 GABRA1 (0.95) GABRA1GABRB2CA2CYP3A4HPGD
Hydrogen Peroxide SCHEMBL28937397 0.78 GABRA1 (0.95) GABRA1GABRB2CA2CYP3A4HPGD
Ethane SCHEMBL5264203 0.78 GABRA1 (0.95) GABRA1GABRB2CA2CYP3A4HPGD
SCHEMBL28800546 0.78 GABRA1 (0.95) GABRA1GABRB2CA2CYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2874664-B1 COMPOSITION FOR THERAPEUTIC USE, INCLUDING AN ORGANIC LIPID PHASE AND A RARE-EARTH RADIOISOTOPE COMPLEX CENTRE EUGENE MARQUIS (FR) 2019-06-19 EP claimed
US-9572770-B2 Stable topical composition and a process for producing a stable topical composition EVIDENCE SOLUCÕES FARMACÊUTICAS LTDA EPP (BR) 2017-02-21 US claimed
EP-2874664-A1 COMPOSITION FOR THERAPEUTIC USE, INCLUDING AN ORGANIC LIPID PHASE AND A RARE- EARTH RADIOISOTOPE COMPLEX Centre Eugene Marquis (FR) 2015-05-27 EP claimed
WO-2014012997-A1 COMPOSITION FOR THERAPEUTIC USE, INCLUDING AN ORGANIC LIPID PHASE AND A RARE- EARTH RADIOISOTOPE COMPLEX CENTRE EUGENE MARQUIS (FR) 2014-01-23 WO claimed
US-20130123220-A1 Stable Topical Composition and a Process for Producing a Stable Topical Composition EVIDENCE SOLUÇÕES FARMACÊUTICAS LTDA EPP (BR) 2013-05-16 US claimed
WO-2012009778-A2 A STABLE TOPICAL COMPOSITION AND A PROCESS FOR PRODUCING A STABLE TOPICAL COMPOSITION EVIDENCE SOLUÇÕES FARMACÊUTICAS LTDA EPP (BR) 2012-01-26 WO claimed
EP-1705227-A2 New dyestuffs and colorants with specific carbonyl compounds Henkel Kommanditgesellschaft auf Aktien (DE) 2006-09-27 EP claimed
US-11826452-B2 Reduction of tooth staining derived from cationic antimicrobials THE PROCTER & GAMBLE COMPANY (US) 2023-11-28 US disclosed
US-20220257484-A1 WHOLE MOUTH MALADOR CONTROL BY A COMBINATION OF ANTIBACTERIAL AND DEODORIZING AGENTS PROCTER & GAMBLE (US) 2022-08-18 US disclosed
US-20220105012-A1 REDUCTION OF TOOTH STAINING DERIVED FROM CATIONIC ANTIBACTERIALS PROCTER & GAMBLE (US) 2022-04-07 US disclosed
US-11253451-B2 Reduction of tooth staining derived from cationic antibacterials THE PROCTER & GAMBLE COMPANY (US) 2022-02-22 US disclosed
US-20220047484-A1 Reduction Of Tooth Staining Derived From Cationic Antimicrobials PROCTER & GAMBLE (US) 2022-02-17 US disclosed
US-11191709-B2 Reduction of tooth staining derived from cationic antimicrobials THE PROCTER & GAMBLE COMPANY (US) 2021-12-07 US disclosed
WO-2003041669-A1 A COMPOSITION FOR PROMOTING HAIR GROWTH LG HOUSEHOLD & HEALTH CARE LTD. (KR) 2003-05-22 WO disclosed
EP-0952852-A1 STABILIZED HINOKITIOL AND COMPOSITIONS CONTAINING SAME E-L Management Corp. (US) 1999-11-03 EP disclosed
EP-0952852-A4 1999-11-03 EP disclosed
US-5811114-A COSMETICS OR DRUGS PRESERVED BY MICROCAPSULES CONTAINING HINOKITIOL E-L MANAGEMENT CORP. (US) 1998-09-22 US disclosed
WO-1997047289-A1 STABILIZED HINOKITIOL AND COMPOSITIONS CONTAINING SAME E-L MANAGEMENT CORPORATION (US) 1997-12-18 WO disclosed
EP-0108622-B1 SYNTHETIC RESIN COMPOSITION AND PROCESS FOR PRODUCING THE SAME MITSUBISHI RAYON CO., LTD. (JP) 1988-03-02 EP disclosed
US-4563494-A LANTHANOID COMPOUND MITSUBISHI RAYON CO., LTD. (JP) 1986-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11826452-B2 Reduction of tooth staining derived from cationic antimicrobials PHOSPHO1, PEF1, DNM1L GABRA1 4513/4885GABRB2 4676/4885CA2 3092/4885
US-20220047484-A1 Reduction Of Tooth Staining Derived From Cationic Antimicrobials PHOSPHO1, PEF1, DNM1L GABRA1 4513/4885GABRB2 4676/4885CA2 3092/4885
US-20220257484-A1 WHOLE MOUTH MALADOR CONTROL BY A COMBINATION OF ANTIBACTERIAL AND DEODORIZING AGENTS OR10J3, HDAC10, RPP30 GABRA1 3378/4885GABRB2 3523/4885CA2 1273/4885
US-11253451-B2 Reduction of tooth staining derived from cationic antibacterials SOD1, ZRANB2, HDAC10 GABRA1 4722/4885GABRB2 4408/4885CA2 3082/4885
US-20220105012-A1 REDUCTION OF TOOTH STAINING DERIVED FROM CATIONIC ANTIBACTERIALS SOD1, ZRANB2, HDAC10 GABRA1 4722/4885GABRB2 4408/4885CA2 3082/4885
US-11191709-B2 Reduction of tooth staining derived from cationic antimicrobials PHOSPHO1, PEF1, DNM1L GABRA1 4513/4885GABRB2 4676/4885CA2 3092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.